Literature DB >> 33746980

Cell-Mediated Immunological Biomarkers and Their Diagnostic Application in Livestock and Wildlife Infected With Mycobacterium bovis.

Katrin Smith1, Léanie Kleynhans1, Robin M Warren1, Wynand J Goosen1, Michele A Miller1.   

Abstract

Mycobacterium bovis has the largest host range of the Mycobacterium tuberculosis complex and infects domestic animal species, wildlife, and humans. The presence of global wildlife maintenance hosts complicates bovine tuberculosis (bTB) control efforts and further threatens livestock and wildlife-related industries. Thus, it is imperative that early and accurate detection of M. bovis in all affected animal species is achieved. Further, an improved understanding of the complex species-specific host immune responses to M. bovis could enable the development of diagnostic tests that not only identify infected animals but distinguish between infection and active disease. The primary bTB screening standard worldwide remains the tuberculin skin test (TST) that presents several test performance and logistical limitations. Hence additional tests are used, most commonly an interferon-gamma (IFN-γ) release assay (IGRA) that, similar to the TST, measures a cell-mediated immune (CMI) response to M. bovis. There are various cytokines and chemokines, in addition to IFN-γ, involved in the CMI component of host adaptive immunity. Due to the dominance of CMI-based responses to mycobacterial infection, cytokine and chemokine biomarkers have become a focus for diagnostic tests in livestock and wildlife. Therefore, this review describes the current understanding of host immune responses to M. bovis as it pertains to the development of diagnostic tools using CMI-based biomarkers in both gene expression and protein release assays, and their limitations. Although the study of CMI biomarkers has advanced fundamental understanding of the complex host-M. bovis interplay and bTB progression, resulting in development of several promising diagnostic assays, most of this research remains limited to cattle. Considering differences in host susceptibility, transmission and immune responses, and the wide variety of M. bovis-affected animal species, knowledge gaps continue to pose some of the biggest challenges to the improvement of M. bovis and bTB diagnosis.
Copyright © 2021 Smith, Kleynhans, Warren, Goosen and Miller.

Entities:  

Keywords:  Mycobacterium bovis; cell-mediated; cytokines; immunological biomarkers; livestock; wildlife

Year:  2021        PMID: 33746980      PMCID: PMC7969648          DOI: 10.3389/fimmu.2021.639605

Source DB:  PubMed          Journal:  Front Immunol        ISSN: 1664-3224            Impact factor:   7.561


  4 in total

1.  Standardized Whole Blood Assay and Bead-Based Cytokine Profiling Reveal Commonalities and Diversity of the Response to Bacteria and TLR Ligands in Cattle.

Authors:  Jérémy Lesueur; Sarah Walachowski; Sarah Barbey; Nathan Cebron; Rachel Lefebvre; Frédéric Launay; Didier Boichard; Pierre Germon; Fabien Corbiere; Gilles Foucras
Journal:  Front Immunol       Date:  2022-05-23       Impact factor: 8.786

2.  Epidemiology of Mycobacterium bovis infection in free-ranging rhinoceros in Kruger National Park, South Africa.

Authors:  Rebecca Dwyer; Wynand Goosen; Peter Buss; Simon Kedward; Tebogo Manamela; Guy Hausler; Josephine Chileshe; Leana Rossouw; James H Fowler; Michele Miller; Carmel Witte
Journal:  Proc Natl Acad Sci U S A       Date:  2022-06-06       Impact factor: 12.779

3.  Bacterial Ghosts of Pseudomonas aeruginosa as a Promising Candidate Vaccine and Its Application in Diabetic Rats.

Authors:  Salah A Sheweita; Amro A Amara; Heba Gamal; Amany A Ghazy; Ahmed Hussein; Mohammed Bahey-El-Din
Journal:  Vaccines (Basel)       Date:  2022-06-07

4.  Comparison of interferon gamma release assay and CXCL9 gene expression assay for the detection of Mycobacterium bovis infection in African lions (Panthera leo).

Authors:  Rachiel Gumbo; Tashnica T Sylvester; Sven D C Parsons; Peter E Buss; Robin M Warren; Paul D van Helden; Michele A Miller; Tanya J Kerr
Journal:  Front Cell Infect Microbiol       Date:  2022-09-16       Impact factor: 6.073

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.